P-SELECTIN EXPRESSION OF AND PLATELET AGGREGATION UNDER THE ACTION OF DRUGS

Download full text PDF
DOI: https://doi.org/None
Issue: 
3
Year: 
2017

Professor A.L. Urakov (1), MD; A.V. Samorodov (2), MD; Professor F.Kh. Kamilov (2), MD; Professor I.G. Mustafin (3), MD; Professor F.A. Khaliullin (2), PhD 1 - Izhevsk State Medical Academy; 281, Communards St., Izhevsk 426034, Russian Federation; 2 - Bashkir State Medical University; 3, Lenin St., Ufa 450000, Russian Federation; 3 - Kazan State Medical University; 49, Butlerov St., Kazan 420012, Russian Federation

Introduction. P-selectin acts as a leukocyte adhesion receptor and induces the expression of tissue factor on monocytes, resulting in their binding to platelets. The higher expression of P-selectin is indicative of impairments in the hemostatic system. Cytometric analysis of P-selectin expression is commonly used to assess platelet activation. The effect of antiaggregatory drugs on the processes of platelet activation has been inadequately studied. Objective: to compare the level of P-selectin expression and platelet aggregation under the action of antiaggregants of different chemical nature and mechanisms of action in vitro. Material and methods. The investigation objects were drugs used to inhibit platelet aggregation (acetylsalicylic acid, integrilin, tirofiban, and pentoxifylline). Blood from healthy male donors was examined in vitro. Platelet activity was determined simultaneously by induced aggregation and flow cytometry. Results. The most effective glycoprotein IIb-IIIa receptor inhibitors proved to be integrillin and aggrastat. Acetylsalicylic acid and pentoxifylline affected only ADP-induced platelet aggregation. Aspirin failed to substantially inhibit platelet activity in terms of the level of P-selectin expression, despite the fact that the degree of ADP-induced aggregation was significantly decreased. Conclusion. The parameters of standard aggregatometry not always adequately reflect the functional activity of platelets.
Keywords: 
platelet aggregation
P-selectin
acetylsalicylic acid
integrilin
tirofiban
pentoxifylline
References: 
  1. Palabrica T., Lobb R., Furie B.C., Aronovitz M., Benjamin C., Hsu Y.M., Sajer S.A., Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature, 1992; 359: 848–51.
  2. Berger G.L., Hartwell D.W., Wagner D.D. P-Selectin and platelet clearance. Blood, 1998; 92 (11): 4446–52.
  3. Denis C.V., Andre P., Saffaripour S., Wagner D.D. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2001; 98: 4072–7.
  4. Celi A., Pellegrini G., Lorenzet R., De Blasi A., Ready N., Furie B.C., Furie B. P-selectin induces the expression of tissue factor on monocytes. Proceedings of the National Academy of Sciences of the United States of America, 1994; 91: 8767–71.
  5. Cambien B., Wagner D.D. A new role in hemostasis for the adhesion receptor P-selectin. Trends in Molecular Medicine, 2004; 10 (4): 179–186.
  6. Sikka P., Bindra V.K. Emerging antithrombotic drugs: A review. Annals of Tropical Medicine and Public Health, 2011; 4 (2): 138–42.
  7. Dolgov V.V., Svirin P.V. Laboratornaya diagnostika narusheniy. M.: Medicina, 2005; 358. [Dolgov V.V., Svirin P.V. Laboratornaya diagnostika narusheniy. Moscow: Medicina, 2005; 358] (in Russian).
  8. Blair P., Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev., 2009; 23: 177–189.
  9. Vorn G.V. Aggregation of blood platelets by adenosinediphosphate and its reversal. Nature, 1962; 194: 927–9.
  10. Pyatigorskaya N.V., Samylina I.A., Sapozhnikova E`.A., Mit`kina L.I., Lavrenchuk R.A., Bagirova V.L. Voda dlya in``ekciy. Farmaciya, 2010; 5: 3-7. [Pyatigorskaya N.V., Samylina I.A., Sapozhnikova E`.A., Mitkina L.I., Lavrenchuk R.A., Bagirova V.L. Voda dlya in``ekciy. Farmatciya, 2010; 5: 3–7] (in Russian).
  11. Gosudarstvennyy reestr lekarstvennyh sredstv. Tom 2. M.: Medicina, 2004; 1141. [Gosudarstvennyy reestr lekarstvennyh sredstv. Vol. 2. Moscow: Medicina, 2004; 1141] (in Russian).
  12. De Sanctis M.T., Cesarone M.R., Belcaro G., Incandela L., Steigerwalt R., Nicolaides A.N., Griffin M., Geroulakos G. Treatment of retinal vein thrombosis with pentoxifylline: a controlled, randomized trial. Angiology, 2002; 53: 72–3.
  13. Hsu C.Y., Norris J.W., Hogan E.L., Bladin P., Dinsdale H.B., Yatsu F.M., Earnest M.P., Scheinberg P., Caplan L.R., Karp H.R. Pentoxifylline in acute nonhemorrhagic stroke. A randomized, placebo-controlled double-blind trial. Stroke, 1988; 19 (6): 716–22.
  14. Lucas M.A. Prevention of Post-Operative Thrombosis in Peripheral Arteriopathies. Pentoxifylline vs. Conventional Antiaggregants: A Six-Month Randomized Follow-up. Angiology, 1984; 35 (7): 443–50.
  15. Chronos N.A., Wilson D.J., Janes S.L., Hutton R.A., Buller N.P., Goodall A.H. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. Clin Sci (Lond), 1994; 87(5): 575–80.
  16. Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J. Clin. Invest., 1997; 100: 350–6.
  17. Assadian A., Lax J., Meixner-Loicht U., Hagmüller G.W., Bayer P.M., Hübl W. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: Flow cytometric measurement of aspirin-induced platelet inhibition. Journal of Vascular Surgery, 2007; 45 (6): 1142–7.
  18. Li N., Wallén N.H., Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation, 1999; 100:1374–9.
  19. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol., 2003; 41: 961–5.
  20. Chen W-H., Cheng X., Lee P.Y., Tse H.F., Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol., 2004; 43: 1122–6.
  21. Patrono C., Coller B., FitzGerald G.A., Hirsh J., Roth G. Platelet-active drugs: the relationships among dose, ectiveness, and side effects. Chest., 2004; 126 (234): 64.
  22. Chen Z.M., Jiang L.X., Chen Y.P. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005; 366: 1607–21.